<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00532077</url>
  </required_header>
  <id_info>
    <org_study_id>CR9108122</org_study_id>
    <nct_id>NCT00532077</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effects of SB-751689 or rhPTH(1-34) on Excretion of Calcium and Phosphate in Women</brief_title>
  <official_title>An Exploratory, Open Label, Multicenter Parallel Group Study to Evaluate the Effects of Single and Repeat Dosing of SB-751689 (400 mg or 100 mg) or rhPTH(1-34) on the Fractional Renal Excretion of Calcium and Phosphate in Healthy Postmenopausal Females.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      SB-751689 may alter calcium and phosphate handling at the kidney level. This study will&#xD;
      examine what happens to calcium and phosphate, and other electrolytes, at the kidney after&#xD;
      treatment with SB-751689 for 1 month. Another group of subjects will get another drug called&#xD;
      Forteo for 1 month to compare the response of the kidney for calcium and phosphate.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>renal fractional clearance of calcium and phosphate</measure>
    <time_frame>over 1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>renal fraction clearance of electrolytes, cAMP, safety measures, and serum biomarkers</measure>
    <time_frame>over 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urinary excretion of sodium, magnesium, potassium, bicarbonate, and chloride</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Albumin-adjusted serum calcium levels</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vitamin D and P1NP levels</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma levels of SB-751689 and rhPTH(1-34)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PTH</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event reports, 12-lead ECGs, vital signs, nursing/physician observation and laboratory tests.</measure>
  </secondary_outcome>
  <enrollment type="Actual">40</enrollment>
  <condition>Osteoporosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhPTH(1-34)</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SB-751689 100 mg</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SB-751689 400 mg</intervention_name>
    <other_name>rhPTH(1-34)</other_name>
    <other_name>SB-751689 100 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy postmenopausal women 40 to 65 years of age, inclusive, meeting at least one of&#xD;
             the following: Postmenopausal defined by the STRAW criteria of 12 months of&#xD;
             spontaneous amenorrhea with serum FSH levels = 40 mIU/mL; History of bilateral&#xD;
             oophorectomy (with or without hysterectomy) and at least 6 weeks post-surgical with&#xD;
             serum FSH levels = 40 mIU/mL&#xD;
&#xD;
          -  Body weight &gt; 50 kg and BMI within the range 19 - 32 kg/m2&#xD;
&#xD;
          -  Capable of giving written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any clinically relevant biological or physical abnormality found or reported at&#xD;
             screening which, in the opinion of the investigator, is clinically significant and&#xD;
             would preclude safe participation in this study. These abnormalities may be identified&#xD;
             on the screening history and physical or laboratory examination and 12-lead&#xD;
             electrocardiogram (ECG).&#xD;
&#xD;
          -  A subject may not participate in the study if any of the following laboratory results&#xD;
             are above the upper limit of the normal range at screening: liver function tests (ALT,&#xD;
             AST, GGT, alkaline phosphatase, total bilirubin), plasma amylase, glucose, alkaline&#xD;
             phosphatase, or CPK.&#xD;
&#xD;
          -  A subject may not participate in the study if any of the following laboratory results&#xD;
             are outside the normal range at screening: serum levels of albumin-adjusted calcium,&#xD;
             total calcium, PTH, and urinary calcium.&#xD;
&#xD;
          -  A subject with vitamin D deficiency as defined by serum 25-hydroxy vitamin D &lt; 20&#xD;
             ng/mL (equivalent to 50 nmol/L) at screening may not participate in the study. A QTc&#xD;
             interval &gt; 450 msec at screening.&#xD;
&#xD;
          -  Positive urine drug screen.&#xD;
&#xD;
          -  Positive for HIV, hepatitis B virus or hepatitis C virus assays.&#xD;
&#xD;
          -  Urinary cotinine levels indicative of smoking.&#xD;
&#xD;
          -  History of smoking or use of nicotine containing products within one year of&#xD;
             screening.&#xD;
&#xD;
          -  History of regular alcohol consumption&#xD;
&#xD;
          -  History of drug abuse within 6 months of the study.&#xD;
&#xD;
          -  Participation in a study with an investigational drug within 30 days or 5 half-lives&#xD;
             (whichever is longer) preceding the first dose of study medication.&#xD;
&#xD;
          -  Exposure to more than four new chemical entities within 12 months prior to the first&#xD;
             dosing day.&#xD;
&#xD;
          -  Use of prescription or non-prescription drugs, calcium containing antacids, aspirin or&#xD;
             nonsteroidal anti-inflammatory drugs, vitamins, herbal and dietary supplements,&#xD;
             excluding study related vitamin D and calcium supplements, within 14 days prior to the&#xD;
             first dose of study medication.&#xD;
&#xD;
          -  Donation of blood in excess of 500 mL within 56 days prior to dosing.&#xD;
&#xD;
          -  Evidence of hepatic or biliary disease (including cholecystectomy and Gilbert's&#xD;
             Syndrome).&#xD;
&#xD;
          -  Significant renal disease as define by:&#xD;
&#xD;
          -  Serum creatinine clearance &lt;60ml/min (estimated from serum creatinine (SCr) and&#xD;
             demographic data using the MDRD calculation):&#xD;
&#xD;
          -  A validated web-based calculator is found at:&#xD;
             http://nephron.com/cgi-bin/MDRDSIdefault.cgi&#xD;
&#xD;
          -  GFR Calculator&#xD;
&#xD;
          -  To calculate estimated GFR (mL/min/1.73m2) manually:&#xD;
&#xD;
          -  = 186 x (SCr in mg/dL)-1.154 x (age)-0.203 x (0.742 if female) x (1.210 if&#xD;
             African-American)&#xD;
&#xD;
          -  = exp(5.228-1.154 x ln (SCr)-0.203x ln(age)-(0.299 if female) + (0.192 if African&#xD;
             American))&#xD;
&#xD;
          -  Urine protein/creatinine (mg/mg) ratio &gt;2.5; or urine albumin concentration &gt; 300&#xD;
             ug/mg.&#xD;
&#xD;
          -  Known loss of kidney, either surgically or by injury or disease&#xD;
&#xD;
          -  History of significant gastrointestinal&#xD;
&#xD;
          -  History of a gastrointestinal surgical procedure that might affect the absorption of&#xD;
             SB-751689&#xD;
&#xD;
          -  History of sensitivity to any of the study medications or components thereof.&#xD;
&#xD;
          -  History of clinically significant cardiovascular disease.&#xD;
&#xD;
          -  History of pancreatitis or kidney stones. Medical conditions which might alter bone&#xD;
             metabolism&#xD;
&#xD;
          -  Subjects at increased risk of osteosarcoma such as those with Paget's disease of the&#xD;
             bone or any prior external beam or implant radiation therapy involving the skeleton.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials, MD</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78752</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <study_first_submitted>September 17, 2007</study_first_submitted>
  <study_first_submitted_qc>September 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2007</study_first_posted>
  <disposition_first_submitted>October 13, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>October 13, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 19, 2010</disposition_first_posted>
  <last_update_submitted>October 13, 2010</last_update_submitted>
  <last_update_submitted_qc>October 13, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2010</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>GSK</organization>
  </responsible_party>
  <keyword>renal,</keyword>
  <keyword>pharmacology,</keyword>
  <keyword>Osteoporosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

